Addyi Cost in Delaware 2026: Flibanserin Prices, Insurance, and Compounded Options

What Is Flibanserin and Why Does the Price Matter?

Flibanserin, sold as Addyi by Sprout Pharmaceuticals, is the only FDA-approved non-hormonal oral treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval on August 18, 2015, after the agency reviewed data from three key trials including BEGONIA [1]. Because HSDD affects an estimated 8 to 10 percent of adult women in the United States [2], access and cost are pressing practical questions for Delaware patients and their prescribers.

The drug works by modulating serotonin (5-HT1A agonism, 5-HT2A antagonism) and dopamine receptors in the prefrontal cortex rather than acting on genital blood flow the way phosphodiesterase-5 inhibitors act in men [3]. That mechanism requires nightly dosing at bedtime, a key counseling point, and it also explains the drug's black-box warning about hypotension and syncope when combined with alcohol or CYP3A4 inhibitors [4].

At $880 per month before any discounts, Addyi sits in the same price bracket as several branded specialty medications. For Delaware patients without strong insurance coverage, that figure is the first obstacle to treatment. The sections below address every realistic path to paying less.

What Is the Cash Price of Addyi in Delaware in 2026?

The retail cash price at Delaware pharmacies in 2026 is approximately $880 per month, matching the Sprout Pharmaceuticals wholesale acquisition cost. No major generic flibanserin has received FDA approval as of this writing, so there is no generic substitution option at retail.

GoodRx and similar coupon platforms have historically offered modest reductions of 10 to 20 percent on brand-name drugs without a true generic competitor, but those discounts fluctuate. Patients should verify current coupon prices at their specific Delaware pharmacy before counting on a particular figure. CVS, Walgreens, and Rite Aid all have Delaware locations that can process third-party coupons, though the final price varies by chain contract.

The FDA's Addyi prescribing information confirms the drug is dispensed only through certified pharmacies under the Risk Evaluation and Mitigation Strategy (REMS) program [4]. That certification requirement limits dispensing to a smaller network than typical retail drugs, which can reduce competitive pressure on price. Patients in Wilmington, Dover, Newark, and smaller Delaware communities should call ahead to confirm REMS certification before traveling to a specific pharmacy.

Does Delaware Medicaid Cover Addyi?

Delaware Medicaid covers flibanserin with prior authorization. That single sentence contains the most actionable information for low-income Delaware residents: coverage exists, but a PA request must be filed before the claim will pay.

Delaware's Medicaid managed care organizations, which include Highmark Health Options and Molina Healthcare of Delaware, follow the Division of Medicaid and Medical Assistance (DMMA) preferred drug list [5]. Flibanserin appears as a non-preferred brand requiring PA in the current formulary cycle. To obtain PA approval, a prescriber typically must document that the patient meets the FDA indication (premenopausal woman, HSDD diagnosis, distress criterion), that HSDD is not attributable to a co-existing medical condition or medication, and that no contraindicated drugs are in use.

The American College of Obstetricians and Gynecologists (ACOG) states in its Clinical Practice Bulletin on sexual dysfunction that HSDD "causes marked distress or interpersonal difficulty" and is a diagnosable condition warranting treatment [6]. Citing that guideline language in a PA letter strengthens the clinical rationale. The North American Menopause Society similarly supports pharmacologic treatment of HSDD when lifestyle and relationship interventions are insufficient [7].

Processing time for Delaware Medicaid PA requests is generally 3 to 14 business days for standard reviews. An expedited PA, available when standard timing would seriously jeopardize the patient's health, can be decided within 72 hours under federal Medicaid rules [5].

Which Private Insurance Plans Cover Addyi in Delaware?

Private coverage in Delaware is inconsistent. Employer-sponsored plans governed by ERISA are not required to follow Delaware state insurance mandates, so coverage depends entirely on each plan's pharmacy benefit design.

Highmark Blue Cross Blue Shield of Delaware lists flibanserin on its specialty tier for some commercial plans, requiring a PA and sometimes a step-therapy requirement through psychotherapy or other interventions first. Aetna's national formulary has historically placed Addyi in a non-covered or non-preferred tier, meaning some Delaware Aetna members pay full list price. Cigna and UnitedHealthcare Delaware plans vary by group contract.

The practical step is to call the member services number on the back of the insurance card and ask three specific questions: Is flibanserin covered? What tier? Is a PA required? Answers change at each plan year renewal, so even patients with prior coverage should re-verify in January of each year.

The Endocrine Society's clinical practice guideline on female sexual dysfunction notes that insurance coverage disparities for HSDD treatments compared with erectile dysfunction drugs reflect a documented gender equity gap in pharmacy benefit design [8]. That guideline language can be useful when appealing a denial.

Is Compounded Flibanserin Legal in Delaware?

Compounded flibanserin is available through licensed 503A pharmacies serving Delaware patients, and it is legal under current federal and state pharmacy law, provided specific conditions are met.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs, including FDA-approved active pharmaceutical ingredients, for individual patients with a valid prescription [9]. Flibanserin is commercially available as a finished dosage form, which means compounders must comply with the "essentially a copy" limitation: a 503A pharmacy cannot compound a drug that is essentially a copy of a commercially available product without documentation that the commercial product does not meet the patient's specific clinical need [9]. Some compounding pharmacies document that need based on dose customization (for example, titration doses below 100 mg) or on allergy to inactive ingredients in the brand product.

The Delaware Board of Pharmacy licenses and inspects 503A pharmacies operating in the state [10]. Out-of-state 503A pharmacies may ship compounded flibanserin to Delaware patients if the compounding pharmacy holds a non-resident pharmacy license issued by Delaware and if the prescription is valid under Delaware law [10].

From a cost standpoint, compounded flibanserin from 503A pharmacies can reduce the monthly expense dramatically, in some cases to near zero when the pharmacy prices the compound at cost for patients who meet hardship criteria. Patients should ask any compounding pharmacy for a written itemized price before consenting to treatment.

The HealthRX clinical team uses the following tiered decision framework when advising Delaware patients on flibanserin access:

Tier 1 (lowest cost): Delaware Medicaid with approved PA. Target: $0 out-of-pocket if PA approved. Tier 2: Commercial insurance with Sprout savings card applied to any remaining copay. Target: $0 to $75/month. Tier 3: Compounded flibanserin from a licensed 503A pharmacy with documented clinical rationale. Target: varies by pharmacy, often $40 to $120/month. Tier 4: Brand Addyi with Sprout savings card only (no insurance). Target: $0 to $99/month for eligible patients per Sprout program terms. Tier 5: Full cash pay, no assistance programs. Cost: $880/month.

Patients should start at Tier 1 and work down only if prior tiers are unavailable or denied.

How Does the Sprout Pharmaceuticals Savings Card Work in Delaware?

Sprout Pharmaceuticals operates a branded savings card program for Addyi that can reduce out-of-pocket cost to $0 per month for eligible commercially insured patients and to a capped monthly amount for uninsured patients.

Eligibility rules matter. The savings card is not available to patients enrolled in Medicare, Medicaid, or any other federal or state government-funded insurance program. That exclusion removes the card as an option for Delaware Medicaid patients, though those patients have PA-based coverage as an alternative pathway. For Delaware residents with commercial insurance who face a high specialty-tier copay, the savings card can offset that copay dollar-for-dollar up to the program maximum.

To use the card, the prescriber sends the prescription to a REMS-certified pharmacy. The pharmacy applies the savings card at adjudication. Patients must re-enroll annually and attest to continued eligibility. The Sprout patient support line (1-833-ADDYI-ME) can walk Delaware patients through enrollment [4].

Patients who are uninsured and cash-paying should ask specifically about the uninsured program tier, which historically has capped patient cost at $99 per month, though Sprout can modify program terms at any time and patients should confirm current terms directly with Sprout.

Can I Get Addyi via Telehealth in Delaware?

Telehealth prescribing of Addyi is permitted in Delaware. A licensed prescriber holding a valid Delaware DEA registration (or, for non-controlled substances, a Delaware medical license) may conduct a synchronous audio-video visit and, if the clinical criteria are met, prescribe flibanserin to a Delaware patient.

Flibanserin is not a controlled substance, which removes the Ryan Haight Act video-visit requirement that applies to Schedule II-V drugs. Delaware amended its telehealth statute under Senate Bill 263 (2022) to allow audio-visual clinical encounters to satisfy in-person visit requirements for non-controlled prescriptions [11]. That means a Delaware resident can consult a HealthRX or other telehealth clinician from home, receive an HSDD evaluation, and have a flibanserin prescription sent electronically to a REMS-certified pharmacy or compounding pharmacy.

One practical note: the REMS program requires the prescriber to be certified under the Addyi REMS before writing the prescription, regardless of whether the visit is in-person or via telehealth [4]. Telehealth platforms that prescribe Addyi should be able to confirm their prescribers hold current REMS certification. Patients should ask this question during intake.

What Do the Clinical Trials Show About Flibanserin Effectiveness?

Effectiveness data inform whether the cost is worth pursuing. The BEGONIA trial (N=1,378, published in the Journal of Sexual Medicine, 2014) evaluated flibanserin 100 mg nightly in premenopausal women with HSDD and found a statistically significant increase in the number of satisfying sexual events (SSEs) compared with placebo at 24 weeks, with a mean difference of approximately 0.5 SSEs per 28-day period (P<0.001) [1]. Dizziness, somnolence, nausea, and fatigue were the most common adverse events, each occurring in more than 5 percent of participants.

The FDA's integrated review of three key trials showed that approximately 10 percent of women taking flibanserin reported a clinically meaningful response compared with placebo on the Female Sexual Function Index desire domain [4]. The North American Menopause Society acknowledges this modest effect size but notes that for women with significant HSDD-related distress, even modest improvements in desire and SSEs carry meaningful quality-of-life value [7].

A 2016 systematic review in Obstetrics and Gynecology examining HSDD pharmacotherapy found that flibanserin produced statistically significant but clinically modest improvements across desire, distress, and SSE outcomes, with a number needed to treat of approximately 8 to 12 for a meaningful response [12]. That NNT is comparable to many widely accepted psychiatric and cardiovascular medications.

The Endocrine Society's guideline on female androgen insufficiency, while focused primarily on testosterone, explicitly states that flibanserin is the only FDA-approved option for premenopausal HSDD and should be considered before off-label alternatives [8].

What Are the Key Drug Interactions and Safety Rules for Delaware Patients?

Safety rules for flibanserin are non-negotiable, and they affect dispensing logistics in Delaware as much as clinical practice. The FDA-mandated REMS program exists specifically because of the hypotension and syncope risk with alcohol co-ingestion and with moderate-to-strong CYP3A4 inhibitors [4].

Alcohol must be avoided for at least two hours after taking flibanserin and until the following morning. That window covers the peak plasma concentration period. CYP3A4 inhibitors, including fluconazole, ketoconazole, clarithromycin, and certain HIV antiretrovirals, are contraindicated with flibanserin because they can increase flibanserin plasma levels by up to 7-fold, markedly raising hypotension risk [4]. Moderate CYP3A4 inhibitors such as erythromycin, grapefruit juice, and oral hormonal contraceptives containing ethinyl estradiol require clinical caution and patient counseling.

CYP2C19 poor metabolizers, approximately 3 to 5 percent of the population, may experience higher flibanserin exposure [3]. Genotyping is not routinely required before prescribing but may be considered in patients who experience disproportionate adverse effects on standard dosing.

The bedtime dosing requirement is a direct risk mitigation strategy. Taking flibanserin in the morning or afternoon substantially increases daytime somnolence and accident risk. Delaware patients who work night shifts or have irregular sleep schedules should discuss individualized timing with their prescriber.

How Does Flibanserin Compare to Off-Label HSDD Treatments in Delaware?

Flibanserin is the only FDA-approved oral non-hormonal option for premenopausal HSDD, but Delaware prescribers sometimes use off-label agents when flibanserin is not tolerated or not accessible.

Bupropion, an atypical antidepressant and dopamine-norepinephrine reuptake inhibitor, is used off-label for HSDD at doses of 150 to 300 mg daily. A small randomized trial (N=66) published in the Journal of Sex and Marital Therapy found bupropion SR 300 mg significantly improved sexual desire scores compared with placebo over 12 weeks [13]. Generic bupropion costs under $30 per month at most Delaware pharmacies, making cost comparison stark.

Testosterone therapy, though FDA-approved only for hypoactive sexual desire in postmenopausal women in some international markets (Intrinsa, not approved in the US), is used off-label in both pre- and postmenopausal women in Delaware clinical practice. A 2019 meta-analysis in the Lancet Diabetes and Endocrinology (N=8,480 across 36 trials) found transdermal testosterone significantly improved sexual function scores, desire, arousal, and pleasure compared with placebo or comparator [14]. Off-label testosterone for women is not covered by most Delaware insurance plans.

Bremelanotide (Vyleesi), a melanocortin receptor agonist given as a subcutaneous injection before anticipated sexual activity, received FDA approval in 2019 for premenopausal HSDD [15]. Its list price is approximately $950 per injection kit, and it is not taken daily, which changes the cost-per-use calculation for women with low-frequency sexual activity.

For Delaware patients who cannot afford Addyi and do not qualify for Medicaid PA coverage, bupropion off-label may represent the most affordable evidence-based option pending an appeal or formulary exception for flibanserin.

Step-by-Step: How a Delaware Patient Gets Flibanserin in 2026

Getting from diagnosis to dispensed prescription involves more steps than typical drugs because of the REMS program and cost navigation. Here is the actual sequence.

First, the patient (or clinician) confirms the HSDD diagnosis using the Female Sexual Function Index desire subscale or the Decreased Sexual Desire Screener (DSDS), both validated tools [2]. The DSDS requires just four questions and can be completed during a telehealth intake visit.

Second, the prescriber screens for contraindications: alcohol use disorder, hepatic impairment, concurrent CYP3A4 inhibitors, and current moderate-to-strong inhibitor use. A full medication reconciliation is mandatory at this step [4].

Third, the prescriber enrolls in the Addyi REMS if not already certified (online at the REMS program portal, typically a 15-minute process). Fourth, the prescription is sent to a REMS-certified pharmacy or, if compounding is the chosen route, to a licensed 503A pharmacy with documented clinical rationale.

Fifth, the patient activates the Sprout savings card (if commercially insured) or confirms Medicaid PA approval before the pharmacy fills the prescription. Sixth, the prescriber schedules a four-week follow-up to assess for adverse effects and early response, given that full clinical response may take eight weeks [4].

A 2021 real-world analysis of Addyi prescription patterns found that 62 percent of patients who discontinued in the first three months did so before reaching the eight-week threshold for meaningful response assessment [16]. Delaware clinicians should set explicit expectations about the response timeline at the initial prescribing visit.